200 related articles for article (PubMed ID: 17664328)
1. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents.
Flynn PM; Rodman J; Lindsey JC; Robbins B; Capparelli E; Knapp KM; Rodriguez JF; McNamara J; Serchuck L; Heckman B; Martinez J;
Antimicrob Agents Chemother; 2007 Oct; 51(10):3516-22. PubMed ID: 17664328
[TBL] [Abstract][Full Text] [Related]
2. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Wang LH; Chittick GE; McDowell JA
Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
[TBL] [Abstract][Full Text] [Related]
4. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.
Anderson PL; Zheng JH; King T; Bushman LR; Predhomme J; Meditz A; Gerber J; Fletcher CV
AIDS; 2007 Sep; 21(14):1849-54. PubMed ID: 17721092
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
Crémieux AC; Katlama C; Gillotin C; Demarles D; Yuen GJ; Raffi F;
Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.
Huang F; Allen L; Huang DB; Moy F; Vinisko R; Nguyen T; Rowland L; MacGregor TR; Castles MA; Robinson P
J Clin Pharm Ther; 2012 Feb; 37(1):81-8. PubMed ID: 21128991
[TBL] [Abstract][Full Text] [Related]
7. Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.
Dumond JB; Reddy YS; Troiani L; Rodriguez JF; Bridges AS; Fiscus SA; Yuen GJ; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2008 Jun; 48(2):156-62. PubMed ID: 18360288
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.
Dumond JB; Yang KH; Kendrick R; Reddy YS; Kashuba AD; Troiani L; Bridges AS; Fiscus SA; Forrest A; Cohen MS
Antimicrob Agents Chemother; 2015 Oct; 59(10):6395-401. PubMed ID: 26239974
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
10. Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.
Bazzoli C; Bénech H; Rey E; Retout S; Salmon D; Duval X; Tréluyer JM; Mentré F;
Antimicrob Agents Chemother; 2011 Jul; 55(7):3423-31. PubMed ID: 21576446
[TBL] [Abstract][Full Text] [Related]
11. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.
Rower JE; Meditz A; Gardner EM; Lichtenstein K; Predhomme J; Bushman LR; Klein B; Zheng JH; Mawhinney S; Anderson PL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3011-9. PubMed ID: 22391541
[TBL] [Abstract][Full Text] [Related]
12. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
13. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
[TBL] [Abstract][Full Text] [Related]
14. Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients.
Robbins BL; Tran TT; Pinkerton FH; Akeb F; Guedj R; Grassi J; Lancaster D; Fridland A
Antimicrob Agents Chemother; 1998 Oct; 42(10):2656-60. PubMed ID: 9756772
[TBL] [Abstract][Full Text] [Related]
15. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
Moore JD; Acosta EP; Johnson VA; Bassett R; Eron JJ; Fischl MA; Long MC; Kuritzkes DR; Sommadossi JP
Antivir Ther; 2007; 12(6):981-6. PubMed ID: 17926654
[TBL] [Abstract][Full Text] [Related]
16. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily.
Yuen GJ; Lou Y; Bumgarner NF; Bishop JP; Smith GA; Otto VR; Hoelscher DD
Antimicrob Agents Chemother; 2004 Jan; 48(1):176-82. PubMed ID: 14693537
[TBL] [Abstract][Full Text] [Related]
17. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
[TBL] [Abstract][Full Text] [Related]
18. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.
Dabis F; Bequet L; Ekouevi DK; Viho I; Rouet F; Horo A; Sakarovitch C; Becquet R; Fassinou P; Dequae-Merchadou L; Welffens-Ekra C; Rouzioux C; Leroy V;
AIDS; 2005 Feb; 19(3):309-18. PubMed ID: 15718842
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.
Moore KH; Barrett JE; Shaw S; Pakes GE; Churchus R; Kapoor A; Lloyd J; Barry MG; Back D
AIDS; 1999 Nov; 13(16):2239-50. PubMed ID: 10563709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
